Tag: cMVO

Arena Pharmaceuticals Announces First Participant Randomized in Phase 2 Trial Evaluating Temanogrel in Coronary Microvascular Obstruction (cMVO)

– Evaluating the safety, tolerability, and efficacy of intravenous (IV) temanogrel for cMVO in adult participants undergoing percutaneous coronary intervention (PCI) – Currently no FDA approved therapies indicated for the treatment of cMVO – Temanogrel was granted FDA Fast Track Designation for the treatment of cMVO PARK CITY, Utah–(BUSINESS WIRE)–Arena […]